Home › Compare › TYOBY vs ABBV
TYOBY yields 4.04% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, TYOBY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TYOBY + ABBV for your $10,000?
Toyobo Co., Ltd. provides films and functional polymers, industrial materials, and healthcare and textile products worldwide. It offers industrial films, including PET films for liquid crystal display, optical, and other industrial use; and synthetic papers. The company also provides packaging films, such as PET, polyolefin, and nylon for food packaging, as well as heat-shrink PET films; functional polymers comprising engineering plastics, industrial adhesives, coatings, photo-sensitive printing plates, acrylate polymers, and electronic materials; rubber and coat processing; and pharmaceuticals intermediates. In addition, it offers functional fibers consisting of airbag fabrics; polyethylene and PBO fibers; functional filters for automobiles, indoor, and anti-pollution solvent adsorption materials and units; and fiber materials for automobile parts. Further, the company provides bio products, including enzymes for diagnostics, diagnostic systems, and reagents for research; artificial kidney hollow fibers; anti-clotting materials; seawater desalination modules; functional textiles for sports clothing, underwear, and uniforms; synthetic filaments; apparel under the Munsingwear brand; acrylic fibers under the Exlan brand; and acrylate fibers under the eks brand, as well as trades in textile products. Additionally, it operates as a contract manufacturer of injections. The company was founded in 1882 and is headquartered in Osaka, Japan.
Full TYOBY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.